“In the third quarter, Cassava Sciences made important progress with simufilam, our lead drug candidate,” said Remi Barbier, President & CEO. “This progress exemplifies our unwavering commitment to develop a new treatment option for people with Alzheimer’s.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
- Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
- Cassava Sciences completes patient enrollment for Phase 3 program of simufilam
- Cassava Sciences put volume heavy and directionally bearish
- Largest borrow rate increases among liquid names